Here is the design of a clinical trial:

Official Title: A Multimodal Intervention to Optimise Antimicrobial Use in Residential Aged Care Facilities (ENGAGEMENT Study): Protocol for a Stepped Wedge Cluster Randomised Trial

Included conditions:
- Antimicrobial Stewardship
- Antibiotics Causing Adverse Effects in Therapeutic Use

Study Armgroups:
- {'label': 'ENGAGEMENT bundle', 'type': 'ACTIVE_COMPARATOR', 'description': 'A multimodal bundle of interventions to optimise antibiotic prescribing in residential aged care facilities. The bundle includes education for nurses and general practitioners caring for residents, telehealth support and implementation of state-wide guidelines.', 'interventionNames': ['Behavioral: Antimicrobial Stewardship ENGAGEMENT bundle']}
- {'label': 'Usual care', 'type': 'PLACEBO_COMPARATOR', 'description': 'Usual facility practices with regards to antibiotic prescribing and review', 'interventionNames': ['Behavioral: Antimicrobial Stewardship ENGAGEMENT bundle']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Antimicrobial Stewardship ENGAGEMENT bundle', 'description': 'Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \\[7\\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:\n\n* Education and engagement of prescribers, nurses, pharmacists and residents and family members\n* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing\n* Guideline development specific to antibiotic use in RACF residents\n* Antimicrobial stewardship team creation in RACF with GP involvement\n* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum\n* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing\n* Telehealth support for key intervention components', 'armGroupLabels': ['ENGAGEMENT bundle', 'Usual care']}

Primary Outcomes:
- {'measure': 'Defined Daily Doses (DDDs) of Antibiotics', 'description': 'The primary outcome measure for this trial is antibiotic use as measured by DDDs of antibiotics per 1000 resident bed days.', 'timeFrame': '18 months'}

Please estimate the sample size based on the assumption: 
82% power, intra class correlation coefficient (ICC) of 0.012, coefficient of variation of 0.3
Sample size
        Sample size was calculated based on the outcome of antibiotic consumption as measured by DDDs. For a trial to run over 20 months with a mean cluster size of 50 residents and a control event rate of 120 DDDs per 1000 resident days [22, 42], 18 RACFs will provide 82% power to detect a 20% reduction in DDDs, which has been demonstrated as feasible by other studies [28, 43] (although these studies have utilised other metrics to quantify antibiotic consumption). The power calculation is based on a conservative intra class correlation coefficient (ICC) of 0.012 and coefficient of variation of 0.3 [44].